Retatrutide
Also listed as JD-3RT
Retatrutide acts on GIP, GLP-1, and glucagon receptors. It is an investigational compound in human trials for weight and metabolic outcomes.
Whole vial: 10 mg / 20 mg / 30 mg / 40 mg Vial math ↓
Why people look it up
Retatrutide draws attention because human trials are studying its effects on body weight, blood sugar, and liver fat through three hormone-receptor pathways.
Body-weight reductionHUMAN CLINICAL EVIDENCE
A phase 2 obesity trial measured substantial weight changes with the trial product. Read source ↗
Blood-sugar controlHUMAN CLINICAL EVIDENCE
A phase 2 type 2 diabetes trial measured glucose-related outcomes. Read source ↗
Liver-fat reductionHUMAN CLINICAL EVIDENCE
A trial analysis measured liver-fat changes in participants with obesity. Read source ↗
The labels show the evidence for each claim. Open a row for its source.
Dosage at a glance
Dosage source summary
- Lower trial group
- 1 mg
- Middle trial groups
- 4 or 8 mg
- Higher trial group
- 12 mg
- How often
- Once weekly in the 2023 phase 2 trial
- Time on / time off
- 48-week study; not a community cycle or titration plan.
- Route
- Subcutaneous trial product.
Separate assigned trial groups, not steps or a protocol for a research vial.
These source amounts do not establish a safe human dose for a research vial.
Sources & individual reports
Separate assigned trial groups, not steps or a protocol for a research vial. Source check: 2026-10-18.
Source coverage: 1 reviewed public account. Not a community consensus.
Report 1 ↗First-person account
- Amount reported
- started at 1 mg; later tried 2 mg, then returned to 1 mg
- How often reported
- not reliably specified in the post
- Reported duration / cycle
- five weeks described
- Route (how it was taken)
- not stated
What the account says: Poster reported nausea and low appetite after increasing the amount. The product was not analytically verified.
Product match & source details
Product match: A self-described retatrutide product, not a verified match to JD-3RT or the trial drug.
r/Retatrutide firsthand post · Posted: date not independently verified · Reviewed: 2026-10-03.
How much agreement is there? Only one directly checked account is shown; the vial and compound identity were not independently authenticated.
Public sources last reviewed: 2026-10-03. Product identity and reported results were not independently verified. Source method →
Evidence, sources & vial math
What the research actually showsHuman studies, evidence limits and mechanisms
What has actually been studied?
Phase 2 trials reported promising results in selected participants. Retatrutide remains investigational; a clinical trial result does not approve or verify a seller's research vial.
Evidence limits: The trial product differs from this research vial. Longer-term outcomes, product identity, and a regimen for this vial are not established.
Product status: Research-vial listings are not FDA-approved medicines. Approved-use labels on this page refer only to the named finished prescription product.
Human research
Retatrutide phase 2 obesity trial 2023
What was found: Body-weight reduction was greater in retatrutide groups than placebo at 24 and 48 weeks.
Main limit: Trial product and selected participants; gastrointestinal events and heart-rate changes were reported. Not a regimen for this vial.
Study setup and amounts
- Who
- Adults with obesity or overweight plus a weight-related condition
- Number of participants
- 338
- Study design
- Randomized, double-blind, placebo-controlled phase 2 trial
- Route
- Subcutaneous
- Amount studied
- Separate 1, 4, 8, and 12 mg target groups; some began at 2 or 4 mg
- Frequency
- Once weekly
- Duration
- 48 weeks
- Outcome measured
- Percentage change in body weight
Study and prescription-product amounts describe those sources. They do not select an amount for an online research vial.
How researchers think it might work
Retatrutide is being studied because it activates three hormone receptors involved in metabolic signaling: GIP, GLP-1, and glucagon.
Show scientific explanation
The phase 2 paper describes retatrutide as a triple receptor agonist and tested its effects on body weight in adults with obesity. Read supporting source ↗
Vial & syringe mathTurn the vial total and liquid volume into concentration and syringe units
Vial & syringe math
Change the vial total and final liquid volume to see what each U-100 syringe mark represents.
The starting 1 mL is a math example. Enter your final mixed volume to update the numbers.
100 U-100 syringe units = 1 mL. These results assume the labeled amount is evenly mixed through the final liquid volume.
See source amounts as syringe units
Human trial groups. These are trial groups, not a step-by-step schedule. Some groups started at 2 or 4 mg before reaching their assigned amount. The studied trial product is not the JD-3RT research vial. Read the Retatrutide phase 2 trial (NEJM, 2023) ↗
| Source row | Amount | Liquid volume | U-100 units | Full amounts in one vial* |
|---|---|---|---|---|
| Trial group | 1 mg | — | — | — |
| Trial group | 4 mg | — | — | — |
| Trial group | 8 mg | — | — | — |
| Trial group | 12 mg | — | — | — |
*Whole amounts by mass, before handling loss. Flags identify amounts above the vial total, volumes above the 100-unit scale, or measurements below one unit. Source amounts describe the named product or study; they do not choose an amount for a research vial.
About this listingResearch-use-only status, seller names and additional background
A research material is not intended for human use. Its name or lab report does not establish suitability for a person. What research use only means →
Why two names? JD-3RT is the seller code connected with Retatrutide in the linked batch records. Check the exact batch; a seller code alone does not verify its contents.
Compiled by PeptideWhy · Scientific sources last checked 2026-10-03 · Editorial policy · Corrections